Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CStone Pharma Starts Phase I Trial of PD-1 Molecule

publication date: May 15, 2018

CStone Pharma of Suzhou has dosed the first patient in a Australian Phase I clinical trial of CS1003, an anti-programmed death-1 (PD-1) candidate aimed at solid tumor cancer. CS1003 is the third CStone molecule to begin clinical testing, joining CS1001 (PD-L1) and CS1002 (CTLA-4). Because CS1003 is cross-reactive with human and mouse PD-1, it allows pre-clinical proof of concept experiments on novel targets. CStone hopes to use the pre-clinical tests to discover and then clinically substantiate first-in-combination efficacy for its checkpoint inhibitors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital